

The rates below are from the Department of Medical Assistance Services (DMAS).

| <u>Code and definition</u> | <u>Effective Date</u> | <u>DMAS FFS Rate (\$)</u> |
|---|------------------------------|----------------------------------|
| COVID Antibody Tests | | |
| 86408: Neutralizing antibody, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) (Coronavirus disease [COVID-19]); screen** | 8/10/2020 | 37.07 |
| 86409: Neutralizing antibody, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]); titer** | 8/10/2020 | 70.06 |
| 86413: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) antibody, quantitative** | 9/8/2020 | 45.26 |
| 0224U: Antibody, severe acute respiratory syndrome coronavirus 2 (SARSCoV-2) (Coronavirus disease [COVID-19]), includes titer(s), when performed** | 6/25/2020 | 37.07 |
| 0226U: Surrogate viral neutralization test (sVNT), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), ELISA, plasma,serum** | 8/10/2020 | 37.21 |
| COVID Multiplex Tests | | |
| 87428: Infectious agent antigen detection by immunoassay technique, (eg, enzyme immunoassay [EIA], enzyme-linked immunosorbent assay [ELISA], fluorescence immunoassay [FIA], immunochemiluminometric assay [IMCA]) qualitative or semiquantitative; severe acute respiratory syndrome coronavirus (eg, SARS-CoV, SARS-CoV-2 [COVID-19]) and influenza virus types A and B | 11/10/2020 | 55.96 |
| 87636: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) and influenza virus types A and B, multiplex amplified probe technique | 10/6/2020 | 125.51 |
| 87637: Infectious agent detection by nucleic acid (DNA or RNA); severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]), influenza virus types A and B, and respiratory syncytial virus, multiplex amplified probe technique | 10/6/2020 | 125.51 |
| 87811: Infectious agent antigen detection by immunoassay with direct optical (ie, visual) observation; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (Coronavirus disease [COVID-19]) | 10/6/2020 | 36.41 |
| 0202U: Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected** | 5/20/2020 | 262.77 |
| 0223U: Infectious disease (bacterial or viral respiratory tract infection), pathogen specific nucleic acid (DNA or RNA), 22 targets including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), qualitative RT-PCR, nasopharyngeal swab, each pathogen reported as detected or not detected** | 6/25/2020 | 262.77 |
| 0225U: Infectious disease (bacterial or viral respiratory tract infection) pathogen-specific DNA and RNA, 21 targets, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), amplified probe technique, including multiplex reverse transcription for RNA targets, each analyte reported as detected or not detected** | 8/10/2020 | 262.77 |
| 0240U: Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 3 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B), upper respiratory specimen, each pathogen reported as detected or not detected | 10/6/2020 | 125.51 |
| 0241U: Infectious disease (viral respiratory tract infection), pathogen-specific RNA, 4 targets (severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2], influenza A, influenza B, respiratory syncytial virus [RSV]), upper respiratory specimen, each pathogen reported as detected or not detected | 10/6/2020 | 125.51 |

| COVID Therapies Code and definition | | |
|---|------------|--------|
| Q0239: Injection, bamlanivimab, 700 mg | 11/10/2020 | 0.01 |
| M0239: Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | 11/10/2020 | 287.75 |
| Q0243: Injection, casirivimab and imdevimab, 2400 mg | 11/21/2020 | 0.01 |
| M0243: Intravenous infusion, casirivimab and imdevimab includes infusion and post administration monitoring | 11/21/2020 | 287.75 |
| Q0245: Injection, bamlanivimab and etesevimab, 2100 mg** | 2/9/2021 | 0.01 |
| M0245: intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring** | 2/9/2021 | 287.75 |
| | | |